{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CLYM",
  "name": "Climb Bio, Inc.",
  "url": "https://orbyd.app/dossiers/CLYM/",
  "json_url": "https://orbyd.app/dossiers/CLYM.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Anti-CD19 autoimmune re-rate: budoprutug's 2026-06-11 EHA ITP data (>90% B-cell depletion, n=15) plus $239.2M cash funding into 2H 2028 lifted CLYM to a 52-week high at $16.33 on 2026-08-14. The 2026-09-03 R&D Spotlight (CLYM116 Phase 1 healthy-volunteer data) is the near binary; the real resolution is four Q4 2026 readouts.",
  "invalidation_trigger": "A daily close below $13.30 gives back the June–July shelf (the $13.36 option strike filed 2026-06-29 marks it) and the pre-Q2-print range; secondarily, the 2026-09-03 R&D Spotlight passing without CLYM116 Phase 1 data supporting the guided Q3 2026 Phase 2 IgAN dosing start.",
  "catalyst_date": "2026-09-03",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage with no approved products and no product revenue; all value is probability-weighted on Phase 1/2 assets.",
    "RA Capital-affiliated entities are reported as 10% owner and director-linked in Form 4 filings, concentrating the register.",
    "resale registration mechanics govern when those shares become freely tradable.",
    "Budoprutug's Orphan Drug and Fast Track designations apply only to primary membranous nephropathy, not to the ITP or SLE programs.",
    "Listed on Nasdaq under CLYM; company-hosted R&D Spotlight events, not just scheduled earnings, have been the primary disclosure vehicle in 2026."
  ],
  "body_markdown": "## Current Thesis\nA pre-revenue B-cell autoimmune story that re-rated on four dated clinical events since May and is now priced at its 52-week high heading into a company-hosted data event on 2026-09-03. The narrative leg being bought: budoprutug (anti-CD19 mAb) delivering deep B-cell depletion across four indications, plus CLYM116 in IgA nephropathy moving into Phase 2 — with $239.2M of cash at 2026-06-30 removing the usual clinical-stage financing overhang until the Q4 2026 readouts land. The 2026-08-14 close of $16.33, RSI(14) 76.8 and 0.0% distance from the 52-week high describe an entry point with no base under it.\n\n## Bull Case\n- **Cash covers the whole readout sequence.** $239.2M in cash, equivalents and marketable securities at 2026-06-30, guided to fund operations \"into the second half of 2028\" (Q2 2026 release, 2026-08-06). Four readouts arrive in Q4 2026 with no funding event forced in between.\n- **Clinical activity is on the board, not promised.** Initial Phase 1b ITP data (EHA, 2026-06-11): 15 heavily pretreated patients, >90% B-cell depletion, higher platelet counts, encouraging safety.\n- **Second asset de-risked on safety.** CLYM116 initial Phase 1 safety data plus translational PK/PD modeling presented at the ERA Congress on 2026-06-05, described as generally well tolerated with no serious adverse events; Phase 2 dosing in IgAN guided to start in Q3 2026.\n- **Regulatory optionality on the lead indication.** Budoprutug holds FDA Orphan Drug and Fast Track designation for primary membranous nephropathy (disclosed 2026-05-05 R&D Spotlight; restated 2026-08-06).\n- **Sell-side is chasing, not fading.** Wedbush reiterated Outperform and raised its target to $20 on 2026-07-27; Truist maintained Buy and raised to $25 on 2026-08-07 — both marks sit above the 2026-08-14 close of $16.33.\n- **Q2 burn is contained relative to the balance.** R&D $9.7M and G&A $5.6M in Q2 2026; net loss $13.5M, EPS $(0.18) against a $(0.21) consensus (2026-08-06).\n\n## Bear Case\n- **The 2026-09-03 event delivers healthy-volunteer Phase 1 data, not efficacy.** Safety and PK in healthy subjects cannot confirm the IgAN thesis; the practical outcome is a Phase 2 go decision, which is already guided. Expectations into a company-hosted event at a 52-week high are the asymmetry.\n- **The re-rate happened before the data.** The 2026-04-28 private placement cleared 9.48M shares at $9.50 for $110.0M. The 2026-08-14 close of $16.33 is far above that clearing price — the entire move is multiple expansion against milestones that mostly resolve in Q4 2026.\n- **Small, single-arm datasets.** The ITP readout is 15 patients, open-label, with B-cell depletion as the mechanistic anchor. Anti-CD19 depletion is a well-mapped biology; depth of depletion has repeatedly failed to translate into durable clinical response in autoimmune indications.\n- **Four Q4 readouts is also four failure surfaces.** pMN (PrisMN), higher-dose ITP cohorts, SLE safety/biomarker and additional CLYM116 Phase 1 all print in the same window; a single disappointing dataset resets the whole cohort's multiple.\n- **Momentum is stretched.** RSI(14) 76.8 with the close sitting exactly at the 52-week high and a 3-month return of +51.2% describes a name with no recent pullback to define support.\n- **No revenue, no approved product.** Every dollar of value is discounted probability of success on assets in Phase 1/2.\n\n## Setup & Price Structure\n- Reference close 2026-08-14: **$16.33**, equal to the 52-week high — 0.0% below it. 3-month return +51.2%. RSI(14) 76.8.\n- The two step-changes are dated: the 2026-07-27 Wedbush target raise to $20 and the 2026-08-06 Q2 print / 2026-08-07 Truist raise to $25. The 52-week high was set the week after both.\n- The last observable shelf before the August leg sits in the low-$13s: a Form 4 option grant on 70,284 shares carries a **$13.36** exercise price struck 2026-06-29, which marks where the stock was trading before the print-and-target-raise sequence. Inference, not a measurement: that area is the first structure a retrace would test.\n- Deeper reference: the **$9.50** April private-placement price. Between $13 and $9.50 there is no dated congestion visible in the events above.\n- Positioning observables, stated as observables: two target raises inside 12 days; a fresh 52-week high; RSI(14) in the high 70s; a company-hosted data event 18 calendar days after the reference close; $110.0M of stock issued at $9.50 in April to institutional buyers now well above water. A Form 4 review through mid-August surfaced option grants (40,000 shares at $10.55 to an RA Capital-designated director; 70,284 shares at $13.36) but no open-market insider sales.\n\n## Catalyst Calendar (next 30 days)\n- **2026-09-03** — R&D Spotlight Event: initial CLYM116 Phase 1 data in healthy volunteers. The binary inside the window.\n- **~2026-09-30 (est.)** — Phase 2 IgAN dosing initiation, guided to Q3 2026. Confirmation or slippage is observable by quarter-end.\n- Just outside the window, and the reason the September event matters as a setup rather than a resolution: **Q4 2026** brings initial pMN (PrisMN) data, higher-dose ITP cohorts, SLE safety and biomarker data, and additional CLYM116 Phase 1 data at a medical meeting.\n\n## What Would Change Our Mind\nThe structure that would break first is the June–July shelf the August leg launched from. **A daily close below $13.30** gives back that entire range and puts the $9.50 April placement price back in play as the next dated reference; on that break the read is a failed pre-catalyst run, not a pullback.\n\nThe second break is calendar, not price: if the 2026-09-03 R&D Spotlight passes without CLYM116 Phase 1 data that supports the guided Q3 Phase 2 IgAN start — or if that dosing start is not confirmed by 2026-09-30 — the two-asset framing narrows to a single Q4-dependent story and the life-cycle label moves toward SATURATED.\n\nThird, fundamentals: any indication that the Q4 2026 pMN, ITP or SLE readouts have slipped into 2027, or a cash balance disclosure in the Q3 10-Q that walks back the \"into the second half of 2028\" runway, breaks the \"funded through the catalysts\" leg outright.\n\nNarrative life-cycle read: **ACCELERATING**, dated by the 2026-06-05 ERA presentation, 2026-06-11 EHA ITP data, the 2026-07-27 and 2026-08-07 target raises, and the 2026-08-14 52-week high. What argues against pressing it here is location, not narrative: fresh entries at a 52-week high with RSI(14) at 76.8, days before a healthy-volunteer dataset, carry the event risk without the structure. A retrace that holds the low-$13s and bases would define far more of the risk.\n\n## Correlation Notes\n- CLYM trades as a clinical-stage autoimmune/nephrology name: correlated to biotech risk appetite (XBI) and to rate expectations, since all value is long-duration probability-weighted cash flow.\n- Direct cohort read-across: IgA nephropathy competitors and B-cell/plasma-cell-directed autoimmune developers. Positive IgAN datasets from larger competitors compress the perceived commercial window for CLYM116; negative ones are read as indication risk across the group.\n- Anti-CD19 and CD19-directed cell-therapy results in lupus and membranous nephropathy set the read-through frame for budoprutug's Q4 SLE and pMN datasets — a competitor failure on depth-of-depletion-to-response translation would hit CLYM without a company-specific event.\n- Idiosyncratic driver on 2026-09-03: this is a company-hosted event with company-controlled disclosure, so the move is unlikely to be sector-driven that day.",
  "first_seen": "2026-08-16",
  "last_analyzed": "2026-08-17T06:09:02+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}